Literature DB >> 21094153

Studies on the effects of heparin products on pregnancy-associated plasma protein A.

Saara Wittfooth1, Risto Tertti, Mauri Lepäntalo, Pekka Porela, Qiu-Ping Qin, Joanna Tynjälä, Outi Inkinen, Juha Perttilä, K E Juhani Airaksinen, Kim Pettersson.   

Abstract

BACKGROUND: Intravenous low molecular weight (LMWH) and unfractionated heparin (UFH) increase the circulating concentrations of pregnancy-associated plasma protein A (PAPP-A), a novel cardiac risk marker, in haemodialysis and coronary angiography patients.
METHODS: To further investigate the mechanisms of heparin effects, free PAPP-A was analysed in serial serum samples collected during haemodialysis (intravenous LMWH), carotid endarterectomy or abdominal aortic aneurysm surgery (intravenous UFH), treatment at intensive care unit (subcutaneous LMWH), and coronary angiography (intravenous bivalirudin). PAPP-A was extracted from plaque tissue samples of endarterectomy and aneurysm patients. The interaction between heparin products and free PAPP-A was studied with gel filtration.
RESULTS: After intravenous UFH and LMWH free PAPP-A increased significantly but bivalirudin had no effect. After LMWH bolus in haemodialysis patients 85% of free PAPP-A was cleared with a half-life of 13.1 min and the rest with a half-life of 96.6 min. Subcutaneous LMWH led to lower and slower free PAPP-A elevation. PAPP-A extracted from plaque tissues was in free form and extraction was strongly enhanced by LMWH. Heparin products increased the molecular size of free PAPP-A.
CONCLUSIONS: The heparin-induced PAPP-A elevation is seen in various patients and should be taken into account when PAPP-A is studied as a biomarker.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21094153     DOI: 10.1016/j.cca.2010.11.024

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

Review 1.  Biomarker tests for risk assessment in coronary artery disease: will they change clinical practice?

Authors:  Johannes Mair; Allan S Jaffe
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

2.  Multi-biomarker strategy for prediction of myocardial dysfunction and mortality in sepsis.

Authors:  Fa-Chao Chen; Yin-Chuan Xu; Zhao-Cai Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2020-07       Impact factor: 3.066

3.  High positive predictive value of PAPP-A for acute coronary syndrome diagnosis in heparin-naïve patients.

Authors:  Petr Hájek; Milan Macek; Martina Pešková; Marie Hladíková; Eva Hansvenclová; Martin Malý; Josef Veselka; Alice Krebsová
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

4.  Myocardial and Peripheral Ischemia Causes an Increase in Circulating Pregnancy-Associated Plasma Protein-A in Non-atherosclerotic, Non-heparinized Pigs.

Authors:  Lasse Bach Steffensen; Christian Bo Poulsen; Jeong Shim; Marie Bek; Kevin Jacobsen; Cheryl A Conover; Jacob Fog Bentzon; Claus Oxvig
Journal:  J Cardiovasc Transl Res       Date:  2015-10-06       Impact factor: 4.132

Review 5.  Managing pregnancy in chronic kidney disease: improving outcomes for mother and baby.

Authors:  Alyssa Fitzpatrick; Fadak Mohammadi; Shilpanjali Jesudason
Journal:  Int J Womens Health       Date:  2016-07-14

6.  A Plaque Disruption Index Identifies Patients with Non-STE-Type 1 Myocardial Infarction within 24 Hours of Troponin Positivity.

Authors:  Maha A Al-Mohaissen; Ronald G Carere; G B John Mancini; Karin H Humphries; Beth A Whalen; Terry Lee; Frank X Scheuermeyer; Andrew P Ignaszewski
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

Review 7.  CT-IGFBP-4 as a Predictive Novel Biomarker of Ischemic Cardiovascular Events and Mortality: A Systematic Review.

Authors:  Abhinav Bhattarai; Pritam Singh Sunar; Sangam Shah; Rajan Chamlagain; Nishan Babu Pokhrel; Pitambar Khanal; Sanjit Kumar Sah; Sujan Poudel; Kapil Belbase; Swati Chand; Rajaram Khanal; Anil Bhattarai
Journal:  J Interv Cardiol       Date:  2022-08-21       Impact factor: 1.776

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.